ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Avacta Appoints Brian Hahn as Chief Financial Officer

LONDON and PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Brian Hahn as Chief Financial Officer (CFO).

Mr Hahn brings more than 25 years of senior financial and operations experience in the biopharmaceutical industry, including a 15-year tenure as CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company’s 2014 initial public offering (IPO) on Nasdaq and the build-out of its finance, accounting, investor relations and corporate affairs functions.

He has worked with life science companies from early stages through product launch, has significant experience in dealing with US healthcare investors, having been involved in multiple IPOs, and has raised over $700 million in capital. He has broad experience in developing strategic plans, business development deals, building strong organizations and establishing strong accounting and control systems which ensure Sarbanes-Oxley compliance.

Mr Hahn currently serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO) and has also served on the Securities and Exchange Commissions’ Advisory Committee on Small and Emerging Companies. Prior to his 15-year tenure at GlycoMimetics, Mr. Hahn held roles of increasing financial leadership responsibility, including Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), and earlier, Senior Accountant with Bering Truck Corporation.

He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

“Brian brings the ideal combination of deep public company experience and understanding of the biotechnology sector that Avacta needs at this transformative stage,” said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta. “His strategic insight and track record of successful financial leadership in clinical-stage companies will be essential as we advance our promising pipeline and prepare for our next phase of growth, including our potential dual listing on the Nasdaq exchange.”

“What drew me to Avacta was not just the company’s innovative technology platforms. It also has a clear vision for revolutionizing cancer treatment through targeted therapies that improve outcomes for patients and their families,” commented Brian Hahn. “The company has built a strong foundation with its pre|CISION® and Affimer® platforms, and I look forward to leveraging my experience to help accelerate Avacta’s growth and strengthen its position in both the U.K. and U.S. capital markets.”

For further information from Avacta, please contact:

Avacta Group plc
Michael Vinegrad, Group Communications
Director
www.avacta.com
  
Peel Hunt (Nomad and Broker)
James Steel / Chris Golden / Patrick Birkholm
www.peelhunt.com

  
ICR Healthcare
Mary-Jane Elliott / Jessica Hodgson / Max Bennett
avacta@consilium-comms.com
  
Investor Contact
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

  
Media Contact
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com

About Avacta www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.